We are dedicated to incubating, launching, and building early-stage companies emerging from leading academic labs and research institutions in regenerative medicine.
Regenerative
medicine is the
future
of healthcare
As our area of focus, regenerative medicine encompasses therapies and enabling technologies that augment, repair, replace, or regenerate organs, tissues, cells, genes, and metabolic processes in the body. These therapies and technologies have the potential to heal or replace tissues and organs damaged by age, disease, trauma, injury, or aberrant repair mechanisms, as well as correct congenital defects. Regenerative medicine aims to alter clinical practice by treating the root causes of disease as opposed to current clinical strategies that focus on symptomatic treatment.
Why now
We believe that breakthroughs in regenerative medicine will be critical to targeting the drivers of disease and accelerating underlying repair processes. Now is the ideal time to build the next generation of companies in this field. Recent developments and emerging trends support our perspective:
- Expanded Toolbox of Enabling Technologies Leading to Improved Understanding of Underlying Biology
- Establishment of Proof-of-Concept and Evolving Maturity of Products in Development
- Rise of Supporting Industries
- Acceleration of Recent Product Approvals and Sales
- Large Pharma Participation and Increasing M&A Activity in Regenerative Medicine
Our competitive advantage
Our team’s long-standing work at the Harvard Stem Cell Institute (HSCI) and many relationships across the renowned Harvard affiliated hospitals give Eos a significant competitive advantage and access to the most promising science and technologies emerging from the institute’s laboratories. Our deep ties to HSCI and the entire Harvard ecosystem, and our team’s extensive work in the regenerative medicine field over more than 15 years, has enabled us to leverage a global network across top academic institutions and research centers around the world.
Eos BioInnovation is investing in curative
therapies and technologies
Menu
Copyright © Eos 2022 - All Rights Reserved
Menu
Copyright © Eos 2022 - All Rights Reserved
Transforming
innovation in
REGENERATIVE MEDICINE
We are dedicated to incubating, launching, and building early-stage companies emerging from leading academic labs and research institutions in regenerative medicine.
Regenerative
medicine is
the future
of healthcare
As our area of focus, regenerative medicine encompasses therapies and enabling technologies that augment, repair, replace, or regenerate organs, tissues, cells, genes, and metabolic processes in the body. These therapies and technologies have the potential to heal or replace tissues and organs damaged by age, disease, trauma, injury or aberrant repair mechanisms, as well as correct congenital defects. Regenerative Medicine aims to alter clinical practice by treating the root causes of disease as opposed to current clinical strategies that focus on symptomatic treatment.
Why now
We believe that breakthroughs in regenerative medicine will be critical to targeting the drivers of disease and accelerating underlying repair processes. Now is the ideal time to build the next generation of companies in this field. Recent developments and emerging trends support our perspective:
- Expanded Toolbox of Enabling Technologies Leading to Improved Understanding of Underlying Biology
- Establishment of Proof-of-Concept and Evolving Maturity of Products in Development
- Rise of Supporting Industries
- Acceleration of Recent Product Approvals and Sales
- Large Pharma Participation and Increasing M&A Activity in Regenerative Medicine
Our competitive advantage
Our team’s long-standing work at the Harvard Stem Cell Institute (HSCI) and many relationships across the renowned Harvard affiliated hospitals give Eos a significant competitive advantage and access to the most promising science and technologies emerging from the institute’s laboratories. Our deep ties to HSCI and the entire Harvard ecosystem, and our team’s extensive work in the regenerative medicine field over more than 15 years, has enabled us to leverage a global network across top academic institutions and research centers around the world.
Eos BioInnovation is investing in curative
therapies and technologies